Novozymes’ First-Half Ebitda Rises 11% Despite Market Uncertainty
09:02 AM | August 11, 2011 | Alex Scott
Novozymes, a biotech firm, says its Ebitda for the first half of the year increased 11% to DK1.6 billion ($306 million) on sales up 9% to DK5.3 billion. All expectations for full-year 2011 are...
This information is only available to subscribers.
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.